S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells

Proteome Science

Yusuke Tanigawara²  Akito Nishimuta²  Yasuko Yamayoshi¹  Sayo Suzuki² 

[1] Hospital Pharmacy, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan;Department of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

关键词: SELDI-TOF MS;    colorectal cancer;    S100A10;    biomarker;    oxaliplatin;   

Others  :  819951
DOI  :  10.1186/1477-5956-9-76

 received in 2011-08-18, accepted in 2011-12-30,  发布年份 2011

【 摘 要 】

Background

Individual responses to oxaliplatin (L-OHP)-based chemotherapy remain unpredictable. The objective of our study was to find candidate protein markers for tumor sensitivity to L-OHP from intracellular proteins of human colorectal cancer (CRC) cell lines. We performed expression difference mapping (EDM) analysis of whole cell lysates from 11 human CRC cell lines with different sensitivities to L-OHP by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), and identified a candidate protein by liquid chromatography/mass spectrometry ion trap time-of-flight (LCMS-IT-TOF).

Results

Of the qualified mass peaks obtained by EDM analysis, 41 proteins were differentially expressed in 11 human colorectal cancer cell lines. Among these proteins, the peak intensity of 11.1 kDa protein was strongly correlated with the L-OHP sensitivity (50% inhibitory concentrations) (P < 0.001, R² = 0.80). We identified this protein as Protein S100-A10 (S100A10) by MS/MS ion search using LCMS-IT-TOF. We verified its differential expression and the correlation between S100A10 protein expression levels in drug-untreated CRC cells and their L-OHP sensitivities by Western blot analyses. In addition, S100A10 protein expression levels were not correlated with sensitivity to 5-fluorouracil, suggesting that S100A10 is more specific to L-OHP than to 5-fluorouracil in CRC cells. S100A10 was detected in cell culture supernatant, suggesting secretion out of cells.

Conclusions

By proteomic approaches including SELDI technology, we have demonstrated that intracellular S100A10 protein expression levels in drug-untreated CRC cells differ according to cell lines and are significantly correlated with sensitivity of CRC cells to L-OHP exposure. Our findings provide a new clue to searching predictive markers of the response to L-OHP, suggesting that S100A10 is expected to be one of the candidate protein markers.

【 授权许可】

   
2011 Suzuki et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol 2000, 18:136-147.
• [2]de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol 2000, 18:2938-2947.
• [3]Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059-2069.
• [4]Grothey A, Sargent D, Goldberg RM, Schmoll H-J: Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. J Clin Oncol 2004, 22:1209-1214.
• [5]Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
• [6]Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin J-C, Ducreux M, Sarasin A, Praz F: ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. Clin Cancer Res 2005, 11:6212-6217.
• [7]Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU//oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91:344-354.
• [8]Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M: Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy. J Clin Oncol 2007, 25:1247-1254.
• [9]Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz H-J: A Xeroderma Pigmentosum Group D Gene Polymorphism Predicts Clinical Outcome to Platinum-based Chemotherapy in Patients with Advanced Colorectal Cancer. Cancer Res 2001, 61:8654-8658.
• [10]Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MKB, Seymour MT: Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial. J Clin Oncol 2008, 26:2690-2698.
• [11]Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ: Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 2005, 230:95-106.
• [12]Maggie Merchant SRW: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000, 21:1164-1177.
• [13]Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
• [14]Okuse K, Malik-Hall M, Baker MD, Poon WY, Kong H, Chao MV, Wood JN: Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature 2002, 417:653-656.
• [15]Donier E, Rugiero F, Okuse K, Wood JN: Annexin II light chain p11 promotes functional expression of acid-sensing ion channel ASIC1a. J Biol Chem 2005, 280:38666-38672.
• [16]van de Graaf SF, Hoenderop JG, Gkika D, Lamers D, Prenen J, Rescher U, Gerke V, Staub O, Nilius B, Bindels RJ: Functional expression of the epithelial Ca(2+) channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex. EMBO J 2003, 22:1478-1487.
• [17]Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, Yacoubi ME, Vaugeois J-M, Nomikos GG, Greengard P: Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States. Science 2006, 311:77-80.
• [18]El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF Jr, Powell SM: Gastric Cancers Overexpress S100A Calcium-binding Proteins. Cancer Res 2002, 62:6823-6826.
• [19]Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z: The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003, 106:327-333.
• [20]Remmelink M, Mijatovic T, Gustin A, Mathieu A, Rombaut K, Kiss R, Salmon I, Decaestecker C: Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. Int J Oncol 2005, 26:247-258.
• [21]Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R: Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Science 2007, 98:77-82.
• [22]Kittaka N, Takemasa I, Takeda Y, Marubashi S, Nagano H, Umeshita K, Dono K, Matsubara K, Matsuura N, Monden M: Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. European Journal of Cancer 2008, 44:885-897.
• [23]Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, Schulenborg T, Marcus K, Luttges J, Dittert DD, Baretton G, Schmiegel W, Hahn SA, Kloppel G, Meyer HE, Stuhler K: Analysis of the Pancreatic Tumor Progression by a Quantitative Proteomic Approach and Immunhistochemical Validation. Journal of Proteome Research 2009, 8:1647-1656.
• [24]MacLeod TJ, Kwon M, Filipenko NR, Waisman DM: Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003, 278:25577-25584.
• [25]Zhang L, Fogg DK, Waisman DM: RNA Interference-mediated Silencing of the S100A10 Gene Attenuates Plasmin Generation and Invasiveness of Colo 222 Colorectal Cancer Cells. J Biol Chem 2004, 279:2053-2062.
• [26]Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, Punt CJ: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009, 45:1999-2006.
• [27]Hsu SY, Kaipia A, Zhu L, Hsueh AJW: Interference of BAD (Bcl-xL/Bcl-2-Associated Death Promoter)-Induced Apoptosis in Mammalian Cells by 14-3-3 Isoforms and P11. Mol Endocrinol 1997, 11:1858-1867.
• [28]Masiakowski P, Shooter EM: Changes in PC12 cell morphology induced by transfection with 42C cDNA, coding for a member of the S-100 protein family. J Neurosci Res 1990, 27:264-269.
• [29]Wu T, Angus CW, Yao XL, Logun C, Shelhamer JH: P11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDa cytosolic phospholipase A2. J Biol Chem 1997, 272:17145-17153.
• [30]Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS: Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-{beta}-Catenin Signaling Axis. Science 2005, 310:1504-1510.
• [31]Sheng H, Shao J, Washington MK, DuBois RN: Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma Cells. Journal of Biological Chemistry 2001, 276:18075-18081.
• [32]Tutton PJ, Barkla DH: Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. Br J Cancer 1982, 46:260-265.
• [33]Xu W, Tamim H, Shapiro S, Stang MR, Collet J-P: Use of antidepressants and risk of colorectal cancer: a nested case-control study. The Lancet Oncology 2006, 7:301-308.
• [34]Li Q, Laumonnier Y, Syrovets T, Simmet T: Plasmin Triggers Cytokine Induction in Human Monocyte-Derived Macrophages. Arterioscler Thromb Vasc Biol 2007, 27:1383-1389.
• [35]Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H: Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 2000, 151:31-38.
• [36]Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
• [37]Svenningsson P, Greengard P: p11 (S100A10) -- an inducible adaptor protein that modulates neuronal functions. Current Opinion in Pharmacology 2007, 7:27-32.
• [38]Lavie Y, Fiucci G, Liscovitch M: Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells. Journal of Biological Chemistry 1998, 273:32380-32383.
• [39]Pang A, Au WY, Kwong YL: Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leukemia Research 2004, 28:973-977.
• [40]Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF: Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005, 118:1493-1503.
• [41]Johnsson N, Marriott G, Weber K: p36, the major cytoplasmic substrate of src tyrosine protein kinase, binds to its p11 regulatory subunit via a short amino-terminal amphiphatic helix. EMBO J 1988, 7:2435-2442.
• [42]Kube E, Becker T, Weber K, Gerke V: Protein-protein interaction studied by site-directed mutagenesis. Characterization of the annexin II-binding site on p11, a member of the S100 protein family. Journal of Biological Chemistry 1992, 267:14175-14182.
• [43]Rety S, Sopkova J, Renouard M, Osterloh D, Gerke V, Tabaries S, Russo-Marie F, Lewit-Bentley A: The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat Struct Mol Biol 1999, 6:89-95.
• [44]Keutzer JC, Hirschhorn RR: The growth-regulated gene 1B6 is identified as the heavy chain of calpactin I. Exp Cell Res 1990, 188:153-159.
• [45]Vishwanatha JK, Kumble S: Involvement of annexin II in DNA replication: evidence from cell-free extracts of Xenopus eggs. J Cell Sci 1993, 105:533-540.
• [46]Chiang Y, Rizzino A, Sibenaller ZA, Wold MS, Vishwanatha JK: Specific down-regulation of annexin II expression in human cells interferes with cell proliferation. Mol Cell Biochem 1999, 199:139-147.
• [47]Gerke V, Creutz CE, Moss SE: Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005, 6:449-461.
• [48]Deora AB, Kreitzer G, Jacovina AT, Hajjar KA: An Annexin 2 Phosphorylation Switch Mediates p11-dependent Translocation of Annexin 2 to the Cell Surface. J Biol Chem 2004, 279:43411-43418.
• [49]Tan Y, Ma SY, Wang FQ, Meng HP, Mei C, Liu A, Wu HR: Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep 2011, 26:853-859.
• [50]Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmstrom J, Ossola R, Watts JD, Lin B, Zhang H, Moritz RL, Aebersold RH: A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 2011, in press.
• [51]Weinberger SR, Boschetti E, Santambien P, Brenac V: Surface-enhanced laser desorption-ionization retentate chromatography(TM) mass spectrometry (SELDI-RC-MS): a new method for rapid development of process chromatography conditions. Journal of Chromatography B 2002, 782:307-316.